Publications

2019

330.
Jagmohan Hooda; Marian Novak; Matthew P. Salomon et al. (2019). Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.  Cancer Research. 79:(4)760-772.  Abstract [All authors]

2018

329.
Noa Furth; Ioannis S. Pateras; Ron Rotkopf et al. (2018). LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.  Life science alliance. 1:(5)  Abstract [All authors]
328.
Waleed Minzel; Avanthika Venkatachalam; Avner Fink et al. (2018). Small Molecules Co-targeting CKI alpha and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.  Cell. 175:(1)171-+.  Abstract [All authors]
327.
Eran Kotler; Odem Shani; Guy Goldfeld et al. (2018). A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.  Molecular Cell. 71:(1)178-190.e8.  Abstract [All authors]
326.
Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project (2018). TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.  Blood. 131:(25)2789-2802.  Abstract
325.
Sharathchandra Arandkar; Noa Furth; Yair Elisha et al. (2018). Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 115:(25)6410-6415.  Abstract [All authors]
324.
Dima Ghannam-Shahbari; Eyal Jacob; Reli Rachel Kakun et al. (2018). PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.  Oncogene. 37:(17)2213-2224.  Abstract [All authors]
323.
Cell Death Collaboration Cell Death Collaboration (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.  Cell Death Differ. 25:(3)486-541.  Abstract
322.
Hilla Solomon; Nathan Dinowitz; Ioannis S. Pateras et al. (2018). Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.  Oncogene. 37:(12)1669-1684.  Abstract [All authors]

2017

321.
Yehoshua Enuka; Morris E. Feldman; Animesh Chowdhury et al. (2017). Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone.  Nucleic Acids Research. 45:(22)12681–12699.  Abstract [All authors]
320.
Yael Aylon; Moshe Oren (2017). Tumor Suppression by p53: Bring in the Hippo!.  Cancer Cell. 32:(4)397-399.  Abstract
319.
A. Spolverini; G. Fuchs; D. R. Bublik; M. Oren (2017). let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery.  Oncogene. 36:(42)5819-5828.  Abstract
318.
W. Minzel; I. Alkalay; Avner Fink et al. (2017). NOVEL SMALL MOLECULE INHIBITORS CO-TARGETING CK1A AND P-TEF-B DISRUPT SUPER-ENHANCERS AND ERADICATE ACUTE MYELOID LEUKEMIA IN A MOUSE MODEL.  Haematologica. 102.  Abstract [All authors]
317.
Ayala Tovy; Adam Spiro; Ryan McCarthy et al. (2017). p53 is essential for DNA methylation homeostasis in naive embryonic stem cells, and its loss promotes clonal heterogeneity.  GENES & DEVELOPMENT. 31:(10)959-972.  Abstract [All authors]
316.
Ohad Tarcic; Roy Z Granit; Ioannis S Pateras et al. (2017). RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.  Cell Death and Differentiation. 24:(4)694-704.  Abstract [All authors]
315.
Debora R. Bublik; Sladana Bursac; Michal Sheffer et al. (2017). Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival.  Proceedings of the National Academy of Sciences of the United States of America. 114:(4)E496-E505.  Abstract [All authors]

2016

314.
Moshe Oren; Eran Kotler (2016). p53 mutations promote proteasomal activity.  Nature Cell Biology. 18:(8)833-835.  Abstract
313.
Kristin Stock; Marta F. Estrada; Suzana Vidic et al. (2016). Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.  Scientific Reports. 6.  Abstract [All authors]
312.
Yael Aylon; Moshe Oren (2016). The Hippo pathway, p53 and cholesterol.  Cell cycle (Georgetown, Tex.). 15:(17)2248-55.  Abstract
311.
Ines Orsolic; Deana Jurada; Nick Pullen; Moshe Oren; Aristides G. Eliopoulos; Sinisa Volarevic (2016). The relationship between the nucleolus and cancer: Current evidence and emerging paradigms.  Seminars in Cancer Biology. 37-38:36-50.  Abstract
310.
Moshe Oren; Perry Tal; Varda Rotter (2016). Targeting mutant p53 for cancer therapy.  AGING-US. 8:(6)1159-1160.
309.
Rona Yaeger; Manish A Shah; Vincent A Miller et al. (2016). Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.  Gastroenterology. 151:(2)278-287.e6.  Abstract [All authors]
308.
Yael Aylon; Anat Gershoni; Ron Rotkopf et al. (2016). The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation.  GENES & DEVELOPMENT. 30:(7)786-97.  Abstract [All authors]
307.
Perry Tal; Shay Eizenberger; Elad Cohen; Naomi Goldfinger; Shmuel Pietrokovski; Moshe Oren; Varda Rotter (2016). Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.  Oncotarget. 7:(11)11817-11837.  Abstract
306.
Ohad Tarcic; Ioannis S. Pateras; Tomer Cooks et al. (2016). RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer.  Cell Reports. 14:(6)1462-1476.  Abstract [All authors]
305.
Yonit Hoffman; Debora Rosa Bublik; Alejandro P Ugalde; Ran Elkon; Tammy Biniashvili; Reuven Agami; Moshe Oren; Yitzhak Pilpel (2016). 3 ' UTR Shortening Potentiates MicroRNA-Based Repression of Pro-differentiation Genes in Proliferating Human Cells.  PLoS Genetics. 260-262.  Abstract
304.
Moshe Oren; Noa Furth; Noa Bossel Ben-Moshe; Ziv Porat; Eytan Domany; Yair Pozniak; Tamar Geiger; Yael Aylon (2016). Tumor suppressor crosstalk: Modulation of p53 activity by the Hippo pathway.  Cancer Research. 76:(2016)

2015

303.
Noa Furth; Ben-Moshe, Noa Bossel Ben-Moshe; Yair Pozniak; Ziv Porat; Tamar Geiger; Eytan Domany; Yael Aylon; Moshe Oren (2015). Down-regulation of LATS kinases alters p53 to promote cell migration.  GENES & DEVELOPMENT. 29:(22)2325-30.  Abstract
302.
SA Harel; NB Ben-Moshe; Yael Aylon et al. (2015). Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.  Cell Death and Differentiation. 22:(8)1328-1340.  Abstract [All authors]
301.
Gilad Fuchs; Yoav Voichek; Michal Rabani; Sima Benjamin; Shlomit Gilad; Ido Amit; Moshe Oren (2015). Simultaneous measurement of genome-wide transcription elongation speeds and rates of RNA polymerase II transition into active elongation with 4sUDRB-seq.  Nature Protocols. 10:(4)605-618.  Abstract
300.
Lior Golomb; Adi Sagiv; I.S. Pateras; A. Maly; Valery Krizhanovsky; V.G. Gorgoulis; Moshe Oren; A. Ben-Yehuda (2015). Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy.  Cell Death and Differentiation. 22:(11)1764-1774.  Abstract
299.
Moshe Oren; Sharath Chandra Arundkar (2015). P53-dependent non-coding RNA networks in chronic lymphocytic leukemia.  Leukemia. 29:(10)2015-2023.  Abstract

2014

298.
Audrey Lasry; Dvir Aran; Adar Zinger et al. (2014). Parainflammation in cancer.  Cytokine. 70:(1)22-22.  Abstract [All authors]
297.
Gilad Fuchs; D Hollander; Yoav Voichek; G Ast; Moshe Oren (2014). Cotranscriptional histone H2B monoubiquitylation is tightly coupled with RNA polymerase II elongation rate.  Genome Research. 24:(10)1572-1583.  Abstract
296.
Lior Golomb; Sinisa Volarevic; Moshe Oren (2014). p53 and ribosome biogenesis stress: The essentials.  FEBS Letters. 588:(16)2571-2579.  Abstract
295.
Tomer Cooks; CC Harris; Moshe Oren (2014). Caught in the cross fire: p53 in inflammation.  Carcinogenesis. 35:(8)1680-1690.  Abstract
294.
Gilad Fuchs; Moshe Oren (2014). Writing and reading H2B monoubiquitylation.  Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms. 1839:(8)694-701.  Abstract
293.
A. Weilbacher; M. Gutekunst; Moshe Oren; W. E. Aulitzky; der Kuip, H. van der Kuip (2014). RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.  Cell Death & Disease. 5.  Abstract
292.
A Lasry; H Hamza; E Kadosh et al. (2014). Parainflammation in cancer.  European Journal of Cancer. 50:S18-S18.  Abstract [All authors]
291.
Ohad Tarcic; Moshe Oren (2014). Proffered Paper: Regulation of NF-kB, inflammation and cancer by the E3 ligase RNF20.  European Journal of Cancer. 50:S16-S17.  Abstract
290.
VE Santo; M Estrada; S Veloso; MFQ Sousa; der Kuip, H Van der Kuip; Moshe Oren; ER Boghaert; PM Alves; C Brito (2014). Recapitulation of non-small-cell lung carcinoma microenvironment in perfusion bioreactor cultures: the impact of hypoxia on tumour-stroma crosstalk.  European Journal of Cancer. 50:S83-S83.  Abstract
289.
Yonit Hoffman; Yitzhak Pilpel; Moshe Oren (2014). microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.  Journal of Molecular Cell Biology. 6:(3)192-197.  Abstract
288.
Yael Aylon; Alona Sarver; A. Tovy; Elena Ainbinder; Moshe Oren (2014). Lats2 is critical for the pluripotency and proper differentiation of stem cells.  Cell Death and Differentiation. 21:(4)624-633.  Abstract
287.
Emma Shtivelman; Michael A. Davies; Patrick Hwu; James Yang; Michal Lotem; Moshe Oren; Keith T. Flaherty; David E. Fisher (2014). Pathways and therapeutic targets in melanoma.  Oncotarget. 5:(7)1701-1752.  Abstract
286.
Yonit Hoffman; D. R. Bublik; Yitzhak Pilpel; Moshe Oren (2014). miR-661 downregulates both Mdm2 and Mdm4 to activate p53.  Cell Death and Differentiation. 21:(2)302-309.  Abstract
285.
Shira Weingarten-Gabbay; D. Khan; N. Liberman; Yael Yoffe; S. Bialik; Sanjib Das; Moshe Oren; Adi Kimchi (2014). The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA.  Oncogene. 33:(5)611-618.  Abstract
284.
Gilad Fuchs; Yoav Voichek; Sima Benjamin; Shlomit Gilad; Ido Amit; Moshe Oren (2014). 4sUDRB-seq: measuring genomewide transcriptional elongation rates and initiation frequencies within cells.  GENOME BIOLOGY. 15:(5)  Abstract

2013

283.
F. Fausti; Agostino, S. Di Agostino; M. Cioce et al. (2013). ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence.  Cell Death and Differentiation. 20:(11)1498-1509.  Abstract [All authors]
282.
Lior Golomb; Moshe Oren (2013). In the race for protection, ARF comes second.  Cell Death and Differentiation. 20:(11)1442-1443.
281.
Hirokazu Suzuki; Norikazu Yabuta; Nobuhiro Okada; Kosuke Torigata; Yael Aylon; Moshe Oren; Hiroshi Nojima (2013). Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis.  Journal of Cell Science. 126:(19)4358-4368.  Abstract
280.
Ariel Pribluda; Ela Elyada; Zoltan Wiener et al. (2013). A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism.  Cancer Cell. 24:(2)242-256.  Abstract [All authors]
279.
Efrat Shema; Miroslav Nikolov; Mahmood Haj-Yahya et al. (2013). Systematic Identification of Proteins Binding to Chromatin-Embedded Ubiquitylated H2B Reveals Recruitment of SWI/SNF to Regulate Transcription.  Cell Reports. 4:(3)601-608.  Abstract [All authors]
278.
Tomer Cooks; Ioannis S. Pateras; Ohad Tarcic et al. (2013). Mutant p53 Prolongs NF-kappa B Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer.  Cancer Cell. 23:(5)634-646.  Abstract [All authors]
277.
Yonit Hoffman; Dvir Dahary; Debora Rosa Bublik; Moshe Oren; Yitzhak Pilpel (2013). The majority of endogenous microRNA targets within Alu elements avoid the microRNA machinery.  Bioinformatics. 29:(7)894-902.  Abstract
276.
Matthias Gutekunst; Thomas Mueller; Andrea Weilbacher; Michael A. Dengler; Moshe Oren; Walter E. Aulitzky; der Kuip, Heiko van der Kuip (2013). Testicular germ cell tumors are hypersensitive to p53 activation based on their Oct-4/Noxa-mediated cellular context rather than on differential p53 activity.  .
275.
Matthias Gutekunst; Thomas Mueller; Andrea Weilbacher; Michael A. Dengler; Jens Bedke; Stephan Kruck; Moshe Oren; Walter E. Aulitzky; der Kuip, Heiko van der Kuip (2013). Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4.  Cancer Research. 73:(5)1460-1469.  Abstract

2012

274.
Sladana Bursac; Maja Cokaric Brdovcak; Martin Pfannkuchen et al. (2012). Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress.  Proceedings of the National Academy of Sciences of the United States of America. 109:(50)20467-20472.  Abstract [All authors]
273.
Gil Hornung; Raz Bar-Ziv; Dalia Rosin; Nobuhiko Tokuriki; Dan Tawfik; Moshe Oren; Naama Barkai (2012). Noise-mean relationship in mutated promoters.  Genome Research. 22:(12)2409-2417.  Abstract
272.
Jens O. Schmid; Meng Dong; Silke Haubeiss et al. (2012). Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin.  Cancer Research. 72:(22)5824-5832.  Abstract [All authors]
271.
J. O. Schmid; M. Dong; S. Haubeiss; G. Friedel; Moshe Oren; T. Muerdter; W. E. Aulitzky; der Kuip, H. van der Kuip (2012). Crosstalk of cancer cells and cancer associated fibroblasts in the p53 response to Cisplatin in intact tissues from NSCLC specimen.  Onkologie. 35:135-135.  Abstract
270.
A. Weilbacher; M. Gutekunst; Moshe Oren; W. Aulitzky; der Kuip, H. van der Kuip (2012). Differential effect of the p53 inducers Nutlin-3 and RITA on cell lines with different p53 status.  Onkologie. 35:195-196.  Abstract
269.
Y. Ben-Neriah; Ariel Pribluda; E. Elyada; I. Snir-Alkalay; E. Pikarsky; Moshe Oren; Z. Wiener; K. Alitalo (2012). Inflammatory control of colorectal cancer progression.  Immunology. 137:158-158.  Abstract
268.
Gilad Fuchs; Efrat Shema; Rita Vesterman et al. (2012). RNF20 and USP44 Regulate Stem Cell Differentiation by Modulating H2B Monoubiquitylation.  Molecular Cell. 46:(5)662-673.  Abstract [All authors]
267.
Gil Hornung; Moshe Oren; Naama Barkai (2012). Nucleosome Organization Affects the Sensitivity of Gene Expression to Promoter Mutations.  Molecular Cell. 46:(3)362-368.  Abstract
266.
Debora Rosa Bublik; Moshe Oren (2012). Get your fingers out of p53's way!.  EMBO Reports. 13:(4)282-283.
265.
Yaara Zwang; Moshe Oren; Yosef Yarden (2012). Consistency Test of the Cell Cycle: Roles for p53 and EGR1.  Cancer Research. 72:(5)1051-1054.  Abstract
264.
Lior Golomb; Debora Rosa Bublik; Sylvia Wilder; Reinat Nevo; Vladimir Kiss; Kristina Grabusic; Sinisa Volarevic; Moshe Oren (2012). Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis.  Molecular Cell. 45:(2)222-232.  Abstract
263.
G. Blandino; W. Deppert; P. Hainaut; A. Levine; G. Lozano; M. Olivier; Varda Rotter; K. Wiman; Moshe Oren (2012). Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop.  Cell Death and Differentiation. 19:(1)180-183.
262.
Mahmood Haj-Yahya; Najat Eltarteer; Shimrit Ohayon; Efrat Shema; Eran Kotler; Moshe Oren; Ashraf Brik (2012). N-Methylation of Isopeptide Bond as a Strategy to Resist Deubiquitinases.  ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 51:(46)11535-11539.

2011

261.
Moshe Oren; Yael Aylon; E. Shema; Gilad Fuchs (2011). Tumour Suppressor Networks: Lessons From p53.  European Journal of Cancer. 47:S54-S55.  Abstract
260.
Lior Golomb; Moshe Oren (2011). DePICTing p53 Activation: A New Nucleolar Link to Cancer.  Cancer Cell. 20:(3)283-284.  Abstract
259.
Noa Furth; Moshe Oren (2011). An Aurora A-Lats-Aurora B axis ensures proper chromosome segregation.  Cell Cycle. 10:(18)3054-3055.
258.
Yosef Shiloh; Efrat Shema; Lilach Moyal; Moshe Oren (2011). RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response.  FEBS Letters. 585:(18)2795-2802.  Abstract
257.
Yael Aylon; Moshe Oren (2011). p53: Guardian of ploidy.  Molecular Oncology. 5:(4)315-323.  Abstract
256.
Mirko Tarocchi; Rebekka Hannivoort; Yujin Hoshida et al. (2011). Carcinogen-Induced Hepatic Tumors in KLF6+/- Mice Recapitulate Aggressive Human Hepatocellular Carcinoma Associated with p53 Pathway Deregulation.  Hepatology. 54:(2)522-531.  Abstract [All authors]
255.
Efrat Shema; Moshe Oren; Neri Minsky (2011). Detection and characterization of ubiquitylated H2B in mammalian cells.  Methods. 54:(3)326-330.  Abstract
254.
Efrat Shema; Jaehoon Kim; Robert G. Roeder; Moshe Oren (2011). RNF20 Inhibits TFIIS-Facilitated Transcriptional Elongation to Suppress Pro-oncogenic Gene Expression.  Molecular Cell. 42:(4)477-488.  Abstract
253.
Stefania Dell'Orso; Giulia Fontemaggi; Perry Stambolsky et al. (2011). ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters.  Omics-A Journal Of Integrative Biology. 15:(5)305-312.  Abstract [All authors]
252.
Yaara Zwang; Aldema Sas-Chen; Yotam Drier et al. (2011). Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals.  Molecular Cell. 42:(4)524-535.  Abstract [All authors]
251.
Matthias Gutekunst; Moshe Oren; Andrea Weilbacher; Michael A. Dengler; Christiane Markwardt; Juergen Thomale; Walter E. Aulitzky; der Kuip, Heiko van der Kuip (2011). p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin.  PLoS One. 6:(4)  Abstract
250.
Ela Elyada; Ariel Pribluda; Robert E. Goldstein et al. (2011). CKI alpha ablation highlights a critical role for p53 in invasiveness control.  Nature. 470:(7334)409-U208.  Abstract [All authors]
249.
Yael Aylon; Moshe Oren (2011). New plays in the p53 theater.  Current opinion in genetics & development. 21:(1)86-92.  Abstract
248.
Ido Goldstein; V. Marcel; M. Olivier; Moshe Oren; Varda Rotter; P. Hainaut (2011). Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.  Cancer Gene Therapy. 18:(1)2-11.  Abstract
247.
Nobuhiro Okada; Norikazu Yabuta; Hirokazu Suzuki; Yael Aylon; Moshe Oren; Hiroshi Nojima (2011). A novel Chk1/2-Lats2-14-3-3 signaling pathway regulates P-body formation in response to UV damage.  Journal of Cell Science. 124:(1)57-67.  Abstract

2010

246.
Yoseph Addadi; Neta Moskovits; Dorit Granot; Guillermina Lozano; Yaron Carmi; Ron N. Apte; Michal Neeman; Moshe Oren (2010). p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner.  Cancer Research. 70:(23)9650-9658.  Abstract
245.
Yael Aylon; Yaara Ofir-Rosenfeld; Norikazu Yabuta; Eleonora Lapi; Hiroshi Nojima; Xin Lu; Moshe Oren (2010). The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.  GENES & DEVELOPMENT. 24:(21)2420-2429.  Abstract
244.
Efrat Lidor Nili; Yair Field; Yaniv Lubling; Jonathan Widom; Moshe Oren; Eran Segal (2010). p53 binds preferentially to genomic regions with high DNA-encoded nucleosome occupancy.  Genome Research. 20:(10)1361-1368.  Abstract
243.
Ruth Scherz-Shouval; Hilla Weidberg; Chagay Gonen; Sylvia Wilder; Zvulun Elazar; Moshe Oren (2010). p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation.  Proceedings of the National Academy of Sciences of the United States of America. 107:(43)18511-18516.  Abstract
242.
Moshe Oren (2010). p53 and cancer: a complex affair.  Ejc Supplements. 8:(5)83-83.  Abstract
241.
Reut Shalgi; Yitzhak Pilpel; Moshe Oren (2010). Repression of transposable-elements - a microRNA anti-cancer defense mechanism?.  Trends in Genetics. 26:(6)253-259.  Abstract
240.
Tobias Schilling; Astrid Kairat; Gerry Melino; Peter H. Krammer; Wolfgang Stremmel; Moshe Oren; Martina Mueller (2010). Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.  Biochemical and Biophysical Research Communications. 394:(3)817-823.  Abstract
239.
Moshe Oren; Tomer Cooks (2010). NF kappa B and p53: A life and death affair.  Cell Cycle. 9:(6)1027-1027.
238.
Perry Stambolsky; Yuval Tabach; Giulia Fontemaggi et al. (2010). Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53.  Cancer Cell. 17:(3)273-285.  Abstract [All authors]
237.
Jair Bar; Neta Moskovits; Moshe Oren (2010). Involvement of stromal p53 in tumor-stroma interactions.  SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY. 21:(1)47-54.  Abstract
236.
N. R. Christoffersen; R. Shalgi; L. B. Frankel et al. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.  Cell Death and Differentiation. 17:(2)236-245.  Abstract [All authors]
235.
Moshe Oren; Varda Rotter (2010). Mutant p53 Gain-of-Function in Cancer.  Cold Spring Harbor perspectives in biology. 2:(2)  Abstract

2009

234.
Ioanna Skorta; Moshe Oren; Christiane Markwardt; Matthias Gutekunst; Walter E. Aulitzky; der Kuip, Heiko van der Kuip (2009). Imatinib Mesylate Induces Cisplatin Hypersensitivity in Bcr-Abl(+) Cells by Differential Modulation of p53 Transcriptional and Proapoptotic Activity.  Cancer Research. 69:(24)9337-9345.  Abstract
233.
Irena Lavelin; Avital Beer; Zvi Kam; Varda Boner; Moshe Oren; Ami Navon; Benjamin Geiger (2009). Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System.  PLoS One. 4:(12)  Abstract
232.
Yael Aylon; N. Yabuta; H. Besserglick; Y. Buganim; Varda Rotter; H. Nojima; Moshe Oren (2009). Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.  Oncogene. 28:(50)4469-4479.  Abstract
231.
Arnold J. Levine; Moshe Oren (2009). The first 30 years of p53: growing ever more complex.  Nature Reviews Cancer. 9:(10)749-758.  Abstract
230.
Tobias Schilling; Elisa Schulze Schleithoff; Astrid Kairat; Gerry Melino; Wolfgang Stremmel; Moshe Oren; Peter H. Krammer; Martina Mueller (2009). Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family.  Biochemical and Biophysical Research Communications. 387:(2)399-404.  Abstract
229.
Reut Shalgi; Ran Brosh; Moshe Oren; Yitzhak Pilpel; Varda Rotter (2009). Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate.  AGING-US. 1:(9)762-770.  Abstract
228.
Jair Bar; Rotem Feniger-Barish; Neta Moskovits; Natalia Lukashchuk; Naomi Goldfinger; Varda Rotter; Glenwood Goss; Moshe Oren (2009). Cancer cells suppress p53 in adjacent fibroblasts.  Journal of Thoracic Oncology. 4:(9)S605-S605.  Abstract
227.
Judith Pirngruber; Andrei Shchebet; Lisa Schreiber et al. (2009). CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3 '-end processing.  EMBO Reports. 10:(8)894-900.  Abstract [All authors]
226.
J. Bar; R. Feniger-Barish; N. Lukashchuk et al. (2009). Cancer cells suppress p53 in adjacent fibroblasts.  Oncogene. 28:(6)933-936.  Abstract [All authors]

2008

225.
Ran Brosh; Reut Shalgi; Atar Liran et al. (2008). p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.  Molecular Systems Biology. 4.  Abstract [All authors]
224.
Yaara Ofir-Rosenfeld; Kristy Boggs; Dan Michael; Michael B. Kastan; Moshe Oren (2008). Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26.  Molecular Cell. 32:(2)180-189.  Abstract
223.
Efrat Shema; Itay Tirosh; Yael Aylon et al. (2008). The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.  GENES & DEVELOPMENT. 22:(19)2664-2676.  Abstract [All authors]
222.
S. Finkin; Yael Aylon; S. Anzi; Moshe Oren; E. Shaulian (2008). Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.  Oncogene. 27:(32)4411-4421.  Abstract
221.
Gianluca Bossi; Francesco Marampon; Revital Maor-Aloni; Bianca Zani; Varda Rotter; Moshe Oren; Sabrina Strano; Giovanni Blandino; Ada Sacchi (2008). Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.  Cell Cycle. 7:(12)1870-1879.  Abstract
220.
Neri Minsky; Efrat Shema; Yair Field; Meromit Schuster; Eran Segal; Moshe Oren (2008). Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells.  Nature Cell Biology. 10:(4)483-490.  Abstract
219.
Yoshinori Abe; Eri Oda-Sato; Kei Tobiume; Keiko Kawauchi; Yoichi Taya; Koji Okamoto; Moshe Oren; Nobuyuki Tanaka (2008). Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.  Proceedings of the National Academy of Sciences of the United States of America. 105:(12)4838-4843.  Abstract

2007

218.
Frida Lantner; Diana Starlets; Yael Gore et al. (2007). CD74 induces TAp63 expression leading to B-cell survival.  Blood. 110:(13)4303-4311.  Abstract [All authors]
217.
Nina Raver-Shapira; Moshe Oren (2007). Tiny actors, great roles - MicroRNAs in p53's service.  Cell Cycle. 6:(21)2656-2661.  Abstract
216.
Ioanna Skorta; der Kuip, Heiko van der Kuip; Martin Henkes; Moshe Oren; Walter E. Aulitzky (2007). Combination of imatinib with cisplatin and nutlin-3: Functional and molecular effects on Bcr-Abl positive cells.  Blood. 110:(11)868A-868A.  Abstract
215.
Xiongbin Lu; Ou Ma; Thuy-Ai Nguyen; Stephen N. Joness; Moshe Oren; Lawrence A. Donehower (2007). The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.  Cancer Cell. 12:(4)342-354.  Abstract
214.
S. Reef; O. Shifman; Moshe Oren; Adi Kimchi (2007). The autophagic inducer smARF interacts with and is stabilized bythe mitochondrial p32 protein.  Oncogene. 26:(46)6677-6683.  Abstract
213.
M. Germann; C. A. Rentsch; A. Wetterwald et al. (2007). Differential expression of the TSC22 domain family of transcription factors in normal prostate and prostate cancer.  BJU International. 100:26-26.  Abstract [All authors]
212.
Yael Aylon; Moshe Oren (2007). Living with p53, dying of p53.  Cell. 130:(4)597-600.  Abstract
211.
Reut Shalgi; Daniel Lieber; Moshe Oren; Yitzhak Pilpel (2007). Global and local architecture of the mammalian microRNA-transcription factor regulatory network.  PLoS Computational Biology. 3:(7)1291-1304.  Abstract
210.
Nina Raver-Shapira; Efi Marciano; Eti Meiri; Yael Spector; Nitzan Rosenfeld; Neta Moskovits; Zvi Bentwich; Moshe Oren (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.  Molecular Cell. 26:(5)731-743.  Abstract
209.
L. Weisz; Moshe Oren; Varda Rotter (2007). Transcription regulation by mutant p53.  Oncogene. 26:(15)2202-2211.  Abstract
208.
Ayelet Shmueli; Moshe Oren (2007). Mdm2: p53's lifesaver?.  Molecular Cell. 25:(6)794-796.
207.
Lilach Weisz; Alexander Damalas; Michalis Liontos et al. (2007). Mutant p53 enhances nuclear factor kappa B activation by tumor necrosis factor alpha in cancer cells.  Cancer Research. 67:(6)2396-2401.  Abstract [All authors]
206.
Moshe Oren; Jiri Bartek (2007). The sunny side of p53.  Cell. 128:(5)826-828.  Abstract

2006

205.
P. Stambolsky; L. Weisz; I. Shats; Yasmin A. Klein; Naomi Goldfinger; Moshe Oren; Varda Rotter (2006). Regulation of AIF expression by p53.  Cell Death and Differentiation. 13:(12)2140-2149.  Abstract
204.
Moshe Oren (2006). Tumor suppression by p53: Inside and outside the cancer cell.  Ejc Supplements. 4:(12)76-76.  Abstract
203.
Neta Moskovits; Alexander Kalinkovich; Jair Bar; Moshe Oren (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts.  Cancer Research. 66:(22)10671-10676.  Abstract
202.
Yael Aylon; Dan Michael; Ayelet Shmueli; Norikazu Yabuta; Hiroshi Nojima; Moshe Oren (2006). A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization.  GENES & DEVELOPMENT. 20:(19)2687-2700.  Abstract
201.
C. A. Rentsch; M. Germann; A. Wetterwald et al. (2006). Transforming growth factor stimulated clone 22 (TSC-22): Potential tumor suppressive role in prostate cancer and novel prostate basal cell marker.  European Urology Supplements. 5:(14)790-790.  Abstract [All authors]
200.
S Reef; Einat Zalckvar; O Shifman; S Bialik; Helena Sabanay; Moshe Oren; Adi Kimchi (2006). A short mitochondrial form of p19(ARF) induces autophagy and caspase-independent cell death.  Molecular Cell. 22:(4)463-475.  Abstract
199.
S Avkin; Ziv Sevilya; L Toube; N Geacintov; SG Chaney; Moshe Oren; Zvi Livneh (2006). p53 and p21 regulate error-prone DNA repair to yield a lower mutation load.  Molecular Cell. 22:(3)407-413.  Abstract
198.
Ira Kogan; Naomi Goldfinger; M Milyavsky et al. (2006). hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.  Cancer Research. 66:(7)3531-3540.  Abstract [All authors]
197.
O Margalit; H Amram; N Amariglio et al. (2006). BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.  Blood. 107:(4)1599-1607.  Abstract [All authors]
196.
MOSHE OREN; ALEXANDER DAMALAS; TANYA GOTTLIEB et al. (2006). Regulation of p53: intricate loops and delicate balances.  Annals of the New York Academy of Sciences. 973:(1)374-383.  Abstract [All authors]
195.
A Zalcenstein; L Weisz; P Stambolsky; J Bar; Varda Rotter; Moshe Oren (2006). Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.  Oncogene. 25:(3)359-369.  Abstract

2005

194.
J Bar; N Lukaschuk; A Zalcenstein; Sylvia Wilder; Rony Seger; Moshe Oren (2005). The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.  Cell Death and Differentiation. 12:(12)1578-1587.  Abstract
193.
M Muller; T Schilling; AE Sayan et al. (2005). TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.  Cell Death and Differentiation. 12:(12)1564-1577.  Abstract [All authors]
192.
O Margalit; H Amram; N Amariglio et al. (2005). BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin's lymphoma.  Blood. 106:(11)50A-50A.  Abstract [All authors]
191.
A Shmueli; Moshe Oren (2005). Life, death, and ubiquitin: Taming the mule.  Cell. 121:(7)963-965.  Abstract
190.
O Gressner; T Schilling; K Lorenz et al. (2005). TAp63 alpha induces apoptosis by activating signaling via death receptors and mitochondria.  EMBO Journal. 24:(13)2458-2471.  Abstract [All authors]
189.
A Oberst; M Rossi; P Salornoni; PP Pandolfi; Moshe Oren; G Melino; F Bernassola (2005). Regulation of the p73 protein stability and degradation.  Biochemical and Biophysical Research Communications. 331:(3)707-712.  Abstract
188.
T Hershko; M Chaussepied; Moshe Oren; D Ginsberg (2005). Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F.  Cell Death and Differentiation. 12:(4)377-383.  Abstract
187.
L Wohlbold; der Kuip, H van der Kuip; A Moehring; G Granot; Moshe Oren; HP Vornlocher; WE Aulitzky (2005). All common p210 and p190 Bcr-abl variants can be targeted by RNA interference.  Leukemia. 19:(2)290-292.
186.
A Damalas; L Weis; SH Nordgard et al. (2005). Mutant p53 exerts its gain of function through activation of the NF-kappa B pathway.  Breast Cancer Research. 7:S53-S53.  Abstract [All authors]

2004

185.
N Minsky; Moshe Oren (2004). The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.  Molecular Cell. 16:(4)631-639.  Abstract
184.
L Wohlbold; der Kuip, H van der Kuip; A Moehring; G Granot; Moshe Oren; HP Vornlocher; WE Aulitzky (2004). Repeated application of sequence-specific siRNA molecules leads to an effective downmodulation of all clinically relevant bcr-abl gene variants.  Blood. 104:(11)165B-165B.  Abstract
183.
L Weisz; A Zalcenstein; P Stambolsky; Yonatan Cohen; Naomi Goldfinger; Moshe Oren; Varda Rotter (2004). Transactivation of the EGR1 gene contributes to mutant p53 gain of function.  Cancer Research. 64:(22)8318-8327.  Abstract
182.
Moshe Oren; MA Iron; A Burcat; JML Martin (2004). Thermodynamic properties of C-1 and C-2 bromo compounds and radicals. A relativistic ab initio study.  Journal of Physical Chemistry A. 108:(38)7752-7761.  Abstract
181.
Y Daniely; G Liao; D Dixon; RI Linnoila; A Lori; SH Randell; Moshe Oren; AM Jetten (2004). Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium.  American Journal Of Physiology-Cell Physiology. 287:(1)C171-C181.  Abstract
180.
Moshe Oren; E Lidor; N Minsky; P Stambolsky; J Taplick; XJ Wang; L Weisz; A Zalcenstein; Varda Rotter (2004). The role of P53 in DNA damage response and apoptosis.  Toxicology and Applied Pharmacology. 197:(3)166-167.  Abstract
179.
E Levina; Moshe Oren; Avri Ben-Ze'ev (2004). Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics.  Oncogene. 23:(25)4444-4453.  Abstract
178.
AD Boese; Moshe Oren; O Atasoylu; JML Martin; M Kallay; J Gauss (2004). W3 theory: Robust computational thermochemistry in the kJ/mol accuracy range.  Journal of Chemical Physics. 120:(9)4129-4141.  Abstract
177.
J Bar; E Cohen-Noyman; Benjamin Geiger; Moshe Oren (2004). Attenuation of the p53 response to DNA damage by high cell density.  Oncogene. 23:(12)2128-2137.  Abstract
176.
G Fiucci; S Beaucourt; D Duflaut et al. (2004). Siah-1b is a direct transcriptional target of p53: Identification of the functional p53 responsive element in the siah-1b promoter.  Proceedings of the National Academy of Sciences of the United States of America. 101:(10)3510-3515.  Abstract [All authors]
175.
XJ Wang; J Taplick; Nitzan Geva; Moshe Oren (2004). Inhibition of p53 degradation by Mdm2 acetylation.  FEBS Letters. 561:(3-Jan)195-201.  Abstract
174.
A Shmueli; Moshe Oren (2004). Regulation of p53 by Mdm2: Fate is in the numbers.  Molecular Cell. 13:(1)4-5.

2003

173.
A Zalcenstein; P Stambolsky; L Weisz; M Muller; David Wallach; TM Goncharov; PH Krammer; Varda Rotter; Moshe Oren (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.  Oncogene. 22:(36)5667-5676.  Abstract
172.
MA Iron; Moshe Oren; JML Martin (2003). Alkali and alkaline earth metal compounds: core-valence basis sets and importance of subvalence correlation.  Molecular Physics. 101:(9)1345-1361.  Abstract
171.
P Ofek; D Ben-Meir; Z Kariv-Inbal; Moshe Oren; Sara Lavi (2003). Cell cycle regulation and p53 activation by protein phosphatase 2C alpha.  Journal of Biological Chemistry. 278:(16)14299-14305.  Abstract
170.
X Wang; A Zalcenstein; Moshe Oren (2003). Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation.  Cell Death and Differentiation. 10:(4)468-476.  Abstract
169.
Moshe Oren (2003). Decision making by p53: life, death and cancer.  Cell Death and Differentiation. 10:(4)431-442.  Abstract
168.
BJ Passer; V Nancy-Portebois; N Amzallag et al. (2003). The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase.  Proceedings of the National Academy of Sciences of the United States of America. 100:(5)2284-2289.  Abstract [All authors]
167.
Dan Yosef Michael; Moshe Oren (2003). The p53-Mdm2 module and the ubiquitin system.  Seminars in Cancer Biology. 13:(1)49-58.  Abstract
166.
I Lavon; E Pikarsky; E Gutkovich; I Goldberg; J Bar; Moshe Oren; Y Ben-Neriah (2003). Nuclear factor-kappa B protects the liver against genotoxic stress and functions independently of p53.  Cancer Research. 63:(1)25-30.  Abstract

2002

165.
G Blander; N Zalle; Y Daniely; J Taplick; MD Gray; Moshe Oren (2002). DNA damage-induced translocation of the Werner helicase is regulated by acetylation.  Journal of Biological Chemistry. 277:(52)50934-50940.  Abstract
164.
M Balass; Edna Kalef; R Maya; Sylvia Wilder; Moshe Oren; E Katchalski-Katzir (2002). Characterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation.  Peptides. 23:(10)1719-1725.  Abstract
163.
Michael Shtutman; Jacob Zhurinsky; Moshe Oren; Elina Levina; Avri Ben-Ze'ev (2002). PML is a target gene of β-catenin and plakoglobin, and coactivates β-catenin-mediated transcription.  Cancer Research. 62:(20)5947-5954.  Abstract
162.
S Courtois; G Verhaegh; S North; MG Luciani; P Lassus; U Hibner; Moshe Oren; P Hainaut (2002). Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.  Oncogene. 21:(44)6722-6728.  Abstract
161.
A Kairat; K Lorenz; Moshe Oren; W Stremmel; P Krammer; M Muller (2002). Differential regulation of the CD95 gene by wild type and mutant p53: Implications for tumorigenesis and therapy resistance.  Hepatology. 36:(4)321A-321A.  Abstract
160.
Z Goldberg; Sionov, R Vogt Sionov; Michael Berger; Yaara Zwang; Rita Perets; Etten, RA Van Etten; Moshe Oren; Y Taya; Y Haupt (2002). Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.  EMBO Journal. 21:(14)3715-3727.  Abstract
159.
XJ Wang; Dan Yosef Michael; Murcia, G de Murcia; Moshe Oren (2002). p53 activation by nitric oxide involves down-regulation of Mdm2.  Journal of Biological Chemistry. 277:(18)15697-15702.  Abstract
158.
S Strano; G Fontemaggi; A Costanzo et al. (2002). Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.  Journal of Biological Chemistry. 277:(21)18817-18826.  Abstract [All authors]
157.
A Folberg-Blum; A Sapir; BZ Shilo; Moshe Oren (2002). Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila.  Oncogene. 21:(15)2413-2417.  Abstract
156.
Dan Yosef Michael; Moshe Oren (2002). The p53 and Mdm2 families in cancer.  Current opinion in genetics & development. 12:(1)53-59.  Abstract
155.
TM Gottlieb; JFM Leal; Rony Seger; Y Taya; Moshe Oren (2002). Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis.  Oncogene. 21:(8)1299-1303.  Abstract

2001

154.
L Susini; BJ Passer; N Amzallag-Elbaz et al. (2001). Siah-1 binds and regulates the function of Numb.  Proceedings of the National Academy of Sciences of the United States of America. 98:(26)15067-15072.  Abstract [All authors]
153.
E Sadot; Benjamin Geiger; Moshe Oren; Avri Ben-Ze'ev (2001). Down-regulation of beta-catenin by activated p53.  Molecular and Cellular Biology. 21:(20)6768-6781.  Abstract
152.
AW Goetz; der Kuip, H van der Kuip; R Maya; Moshe Oren; WE Aulitzky (2001). Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.  Cancer Research. 61:(20)7635-7641.  Abstract
151.
A Damalas; S Kahan; M Shtutman; Avri Ben-Ze'ev; Moshe Oren (2001). Deregulated beta-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation.  EMBO Journal. 20:(17)4912-4922.  Abstract
150.
R Maya; M Balass; ST Kim et al. (2001). ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.  GENES & DEVELOPMENT. 15:(9)1067-1077.  Abstract [All authors]
149.
S Strano; E Munarriz; M Rossi et al. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity.  Journal of Biological Chemistry. 276:(18)15164-15173.  Abstract [All authors]

2000

148.
E Reinstein; M Scheffner; Moshe Oren; A Ciechanover; Alon Schwartz (2000). Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue.  Oncogene. 19:(51)5944-5950.  Abstract
147.
G Blander; N Zalle; JFM Leal; RL Bar-Or; CE Yu; Moshe Oren (2000). The Warner syndrome protein contributes to induction of p53 by DNA damage.  FASEB Journal. 14:(14)2138-2140.
146.
AW Goetz; der Kuip, H van der Kuip; Moshe Oren; WE Aulitzky (2000). Regulation of Mdm-2 protein by physiological growth factors or Bcr-Abl in human and murine hematopoietic cells.  Blood. 96:(11)79A-79A.  Abstract
145.
RL Bar-Or; R Maya; LA Segel; Uri Alon; AJ Levine; Moshe Oren (2000). Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study.  Proceedings of the National Academy of Sciences of the United States of America. 97:(21)11250-11255.  Abstract
144.
S Ries; C Biederer; D Woods; O Shifman; S Shirasawa; T Sasazuki; M McMahon; Moshe Oren; F McCormick (2000). Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19(ARF).  Cell. 103:(2)321-330.  Abstract
143.
S Strano; E Munarriz; M Rossi et al. (2000). Physical and functional interaction between p53 mutants and different isoforms of p73.  Journal of Biological Chemistry. 275:(38)29503-29512.  Abstract [All authors]
142.
R Maya; Moshe Oren (2000). Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure.  Oncogene. 19:(28)3213-3215.  Abstract
141.
R Amson; JM Lassalle; H Halley et al. (2000). Behavioral alterations associated with apoptosis and down-regulation of presenilin 1 in the brains of p53-deficient mice.  Proceedings of the National Academy of Sciences of the United States of America. 97:(10)5346-5350.  Abstract [All authors]
140.
Rozieres, S de Rozieres; R Maya; Moshe Oren; G Lozano (2000). The loss of mdm2 induces p53 mediated apoptosis.  Oncogene. 19:(13)1691-1697.  Abstract

1999

139.
R Khosravi; R Maya; T Gottlieb; Moshe Oren; Y Shiloh; D Shkedy (1999). Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.  Proceedings of the National Academy of Sciences of the United States of America. 96:(26)14973-14977.  Abstract
138.
Moshe Oren (1999). Regulation of the p53 tumor suppressor protein.  Journal of Biological Chemistry. 274:(51)36031-36034.
137.
M Mueller; A Kairat; H Schulze-Bergkamen; SL Friedman; Moshe Oren; PH Krammer; W Stremmel (1999). An intact intronic p53-binding site is a precondition for p53-dependent CD95 gene expression in hepatoma cells.  Hepatology. 30:(4)416A-416A.  Abstract
136.
G Blander; J Kipnis; JFM Leal; CE Yu; GD Schellenberg; Moshe Oren (1999). Physical and functional interaction between p53 and the Werner's syndrome protein.  Journal of Biological Chemistry. 274:(41)29463-29469.  Abstract
135.
JP Roperch; F Lethrone; S Prieur et al. (1999). SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: Identification of common effectors with p53 and p21(Waf1).  Proceedings of the National Academy of Sciences of the United States of America. 96:(14)8070-8073.  Abstract [All authors]
134.
R Agami; G Blandino; Moshe Oren; Yosef Shaul (1999). Interaction of c-Abl and p73 alpha and their collaboration to induce apoptosis.  Nature. 399:(6738)809-813.  Abstract
133.
Moshe Oren; KH Vousden (1999). Hot papers - Cancer research - Mdm2 promotes the rapid degradation of p53 by Y. Haupt, R. Maya, A. Kazaz, M. Oren and Regulation of p53 stability by Mdm2 by M.H.G. Kubbutat, S.N. Jones, K.H. Vousden - Comments.  Scientist. 13:(12)11-11.  Abstract
132.
A Damalas; Avri Ben-Ze'ev; Inbal Simcha; N Shtutman; JFN Leal; J Zhurinsky; Benjamin Geiger; Moshe Oren (1999). Excess beta-catenin promotes accumulation of transcriptionally active p53.  EMBO Journal. 18:(11)3054-3063.  Abstract
131.
Tamar Unger; RV Sionov; E Moallem; CL Yee; PM Howley; Moshe Oren; Y Haupt (1999). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.  Oncogene. 18:(21)3205-3212.  Abstract
130.
XY Zeng; LH Chen; CA Jost et al. (1999). MDM2 suppresses p73 function without promoting p73 degradation.  Molecular and Cellular Biology. 19:(5)3257-3266.  Abstract [All authors]
129.
Tamar Unger; T Juven-Gershon; E Moallem; Michael Berger; RV Sionov; G Lozano; Moshe Oren; Y Haupt (1999). Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.  EMBO Journal. 18:(7)1805-1814.  Abstract
128.
H Lu; X Zeng; L Chen et al. (1999). MDM2 suppresses p73 function without promoting p73 degradation.  FASEB Journal. 13:(7)A1538-A1538.  Abstract [All authors]
127.
A Elkeles; T Juven-Gershon; D Israeli; Sylvia Wilder; A Zalcenstein; Moshe Oren (1999). The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor.  Molecular and Cellular Biology. 19:(4)2594-2600.  Abstract
126.
RV Sionov; E Moallem; Michael Berger; A Kazaz; O Gerlitz; Y Ben-Neriah; Moshe Oren; Y Haupt (1999). c-Abl neutralizes the inhibitory effect of Mdm2 on p53.  Journal of Biological Chemistry. 274:(13)8371-8374.  Abstract
125.
T Juven-Gershon; Moshe Oren (1999). Mdm2: The ups and downs.  Molecular Medicine. 5:(2)71-83.
124.
Moshe Oren; Varda Rotter (1999). Introduction: p53 - the first twenty years.  Cellular and Molecular Life Sciences. 55:(1)9-11.  Abstract
123.
G Blandino; AJ Levine; Moshe Oren (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.  Oncogene. 18:(2)477-485.  Abstract

1998

122.
M Muller; Sylvia Wilder; D Bannasch et al. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.  Journal of Experimental Medicine. 188:(11)2033-2045.  Abstract [All authors]
121.
K Hosokawa; D Aharoni; Ada Dantes et al. (1998). Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells.  Endocrinology. 139:(11)4688-4700.  Abstract [All authors]
120.
M Muller; Sylvia Wilder; D Israeli; SL Friedman; PR Galle; Moshe Oren; W Stremmel; PH Krammer (1998). The CD95 (APO-1/Fas) gene is a DNA-damage-inducible p53 regulated death receptor gene.  Hepatology. 28:(4)167A-167A.  Abstract
119.
TM Gottlieb; Moshe Oren (1998). p53 and apoptosis.  Seminars in Cancer Biology. 8:(5)359-368.  Abstract
118.
YC Wang; G Blandino; Moshe Oren; David Givol (1998). Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs.  Oncogene. 17:(15)1923-1930.  Abstract
117.
G Yardley; Ayelet Zauberman; Moshe Oren; P Jackson (1998). Individual promoter and intron p53-binding motifs from the rat Cyclin G1 promoter region support transcriptional activation by p53 but do not show co-operative activation.  FEBS Letters. 430:(3)171-175.  Abstract
116.
T Juven-Gershon; O Shifman; Tamar Unger; A Elkeles; Y Haupt; Moshe Oren (1998). The Mdm2 oncoprotein interacts with the cell fate regulator numb.  Molecular and Cellular Biology. 18:(7)3974-3982.  Abstract
115.
E Gottlieb; Moshe Oren (1998). p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53.  EMBO Journal. 17:(13)3587-3596.  Abstract
114.
JP Roperch; V Alvaro; S Prieur et al. (1998). Inhibition of presenilin 1 expression is promoted by p53 and p21(WAF-1) and results in apoptosis and tumor suppression.  Nature Medicine. 4:(7)835-838.  Abstract [All authors]
113.
Achiman Ori; Ayelet Zauberman; G Doitsh; N Paran; Moshe Oren; Yosef Shaul (1998). p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.  EMBO Journal. 17:(2)544-553.  Abstract
112.
Moshe Oren (1998). Tumour suppressors - Teaming up to restrain cancer.  Nature. 391:(6664)233-234.

1997

111.
E Shaulian; D Resnitzky; O Shifman; G Blandino; Abraham Amsterdam; A Yayon; Moshe Oren (1997). Induction of Mdm2 and enhancement of cell survival by bFGF.  Oncogene. 15:(22)2717-2725.  Abstract
110.
Ayelet Zauberman; Moshe Oren; Dov Zipori (1997). Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition.  Oncogene. 15:(14)1705-1711.  Abstract
109.
Moshe Oren (1997). Lonely no more: p53 finds its kin in a tumor suppressor haven.  Cell. 90:(5)829-832.
108.
D Israeli; E Tessler; Y Haupt; A Elkeles; Sylvia Wilder; R Amson; Alona Telerman; Moshe Oren (1997). A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis.  EMBO Journal. 16:(14)4384-4392.  Abstract
107.
SL Friedman; E Shaulian; T Littlewood; D Resnitzky; Moshe Oren (1997). Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells.  Oncogene. 15:(1)63-70.  Abstract
106.
PL So; RS Saliba; D Ginsburg; P Gruss; Moshe Oren; ET Stuart (1997). Down-regulation of p53 by PAX5 in lung cancer.  Developmental Biology. 186:(2)A138-A138.  Abstract
105.
Y Haupt; R Maya; A Kazaz; Moshe Oren (1997). Mdm2 promotes the rapid degradation of p53.  Nature. 387:(6630)296-299.  Abstract
104.
EM Ruaro; L Collavin; G DelSal; R Haffner; Moshe Oren; AJ Levine; C Schneider (1997). A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1.  Proceedings of the National Academy of Sciences of the United States of America. 94:(9)4675-4680.  Abstract
103.
E Gottlieb; R Haffner; A King; Gad Asher; P Gruss; P Lonai; Moshe Oren (1997). Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis.  EMBO Journal. 16:(6)1381-1390.  Abstract
102.
R Hansen; Moshe Oren (1997). p53; From inductive signal to cellular effect.  Current opinion in genetics & development. 7:(1)46-51.  Abstract
101.
ME Ruaro; L Collavin; G DelSal; R Haffner; Moshe Oren; A Levine; C Schneider (1997). A proline rich domain in mp53 is required to mediate Gas1 growth inhibitory effect.  European Journal of Cell Biology. 72:31-31.  Abstract

1996

100.
Moshe Oren; C Prives (1996). p53: Upstream, downstream and off stream - Review of the 8th p53 workshop (Dundee, July 5-9, 1996).  Biochimica Et Biophysica Acta-Reviews On Cancer. 1288:(3)R13-R19.
99.
SL Friedman; E Shaulian; Moshe Oren (1996). Does p53 regulate hepatocellular differentiation?.  Hepatology. 24:(4)928-928.  Abstract
98.
O Eizenberg; A FaberElman; E Gottlieb; Moshe Oren; Varda Rotter; Michal Schwartz (1996). p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells.  Molecular and Cellular Biology. 16:(9)5178-5185.  Abstract
97.
P Friedlander; Y Haupt; C Prives; Moshe Oren (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.  Molecular and Cellular Biology. 16:(9)4961-4971.  Abstract
96.
M Nemani; G LinaresCruz; H BruzzoniGiovanelli et al. (1996). Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression.  Proceedings of the National Academy of Sciences of the United States of America. 93:(17)9039-9042.  Abstract [All authors]
95.
N Tanaka; M Ishihara; MS Lamphier et al. (1996). Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage.  Nature. 382:(6594)816-818.  Abstract [All authors]
94.
TM Gottlieb; Moshe Oren (1996). p53 in growth control and neoplasia.  Biochimica Et Biophysica Acta-Reviews On Cancer. 1287:(3-Feb)77-102.
93.
SS Bacus; Yosef Yarden; Moshe Oren et al. (1996). Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.  Oncogene. 12:(12)2535-2547.  Abstract [All authors]
92.
T Bowman; H Symonds; LY Gu; CY Yin; Moshe Oren; T VanDyke (1996). Tissue-specific inactivation of p53 tumor suppression in the mouse.  GENES & DEVELOPMENT. 10:(7)826-835.  Abstract
91.
Y Haupt; Yoav Barak; Moshe Oren (1996). Cell type-specific inhibition of p53-mediated apoptosis by mdm2.  EMBO Journal. 15:(7)1596-1606.  Abstract
90.
U Knippschild; Moshe Oren; W Deppert (1996). Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion.  Oncogene. 12:(8)1755-1765.  Abstract
89.
E Gottlieb; S Lindner; Moshe Oren (1996). Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells.  Cell Growth & Differentiation. 7:(3)301-310.  Abstract
88.
S Rowan; RL Ludwig; Y Haupt; S Bates; X Lu; Moshe Oren; KH Vousden (1996). Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.  EMBO Journal. 15:(4)827-838.  Abstract
87.
Y Haupt; S Rowan; E Shaulian; E Gottlieb; E YonishRouach; K Vousden; Moshe Oren (1996). p53-Mediated apoptosis - Regulatory and mechanistic aspects.  Cancer Genes: Functional Aspects. 7:83-101.  Abstract

1995

86.
SW HIEBERT; G PACKHAM; DK STROM; R HAFFNER; Moshe Oren; G ZAMBETTI; JL CLEVELAND (1995). E2F-1/DP-1 INDUCES P53 AND OVERRIDES SURVIVAL FACTORS TO TRIGGER APOPTOSIS.  Molecular and Cellular Biology. 15:(12)6864-6874.  Abstract
85.
E Harlow; T Tlsty; S Courtneidge et al. (1995). Cancer: The translation of advances in basic science to human therapy. 22-27 July, 1995 - La fondation des Treilles, Tourtour, France - Discussion.  Comptes Rendus De L Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences. 318:(11)1173-1179. [All authors]
84.
Y Haupt; E Gottlieb; S Rowan; E Shaulian; Moshe Oren (1995). The role of P53 in the control of cell death.  European Journal of Cancer. 31A:767-767.  Abstract
83.
ET STUART; R HAFFNER; Moshe Oren; P GRUSS (1995). LOSS OF P53 FUNCTION THROUGH PAX-MEDIATED TRANSCRIPTIONAL REPRESSION.  EMBO Journal. 14:(22)5638-5645.  Abstract
82.
RDG MALCOMSON; Moshe Oren; AH WYLLIE; DJ HARRISON (1995). P53-INDEPENDENT DEATH AND P53-INDUCED PROTECTION AGAINST APOPTOSIS IN FIBROBLASTS TREATED WITH CHEMOTHERAPEUTIC DRUGS.  British Journal of Cancer. 72:(4)952-957.  Abstract
81.
Y HAUPT; S ROWAN; E SHAULIAN; KH VOUSDEN; Moshe Oren (1995). INDUCTION OF APOPTOSIS IN HELA-CELLS BY TRANS-ACTIVATION-DEFICIENT P53.  GENES & DEVELOPMENT. 9:(17)2170-2183.  Abstract
80.
Ayelet Zauberman; D FLUSBERG; Y HAUPT; Yoav Barak; Moshe Oren (1995). A FUNCTIONAL P53-RESPONSIVE INTRONIC PROMOTER IS CONTAINED WITHIN THE HUMAN MDM2 GENE.  Nucleic Acids Research. 23:(14)2584-2592.  Abstract
79.
Ayelet Zauberman; A LUPO; Moshe Oren (1995). IDENTIFICATION OF P53 TARGET GENES THROUGH IMMUNE SELECTION OF GENOMIC DNA - THE CYCLIN-G GENE CONTAINS 2 DISTINCT P53 BINDING-SITES.  Oncogene. 10:(12)2361-2366.  Abstract
78.
D AHARONI; Ada Dantes; Moshe Oren; Abraham Amsterdam (1995). CAMP-MEDIATED SIGNALS AS DETERMINANTS FOR APOPTOSIS IN PRIMARY GRANULOSA-CELLS.  Experimental Cell Research. 218:(1)271-282.  Abstract
77.
I KERENTAL; BS SUH; Ada Dantes; S LINDNER; Moshe Oren; Abraham Amsterdam (1995). INVOLVEMENT OF P53 EXPRESSION IN CAMP-MEDIATED APOPTOSIS IN IMMORTALIZED GRANULOSA-CELLS.  Experimental Cell Research. 218:(1)283-295.  Abstract
76.
Y HAUPT; S ROWAN; Moshe Oren (1995). P53-MEDIATED APOPTOSIS IN HELA-CELLS CAN BE OVERCOME BY EXCESS PRB.  Oncogene. 10:(8)1563-1571.  Abstract
75.
R CORVI; L SAVELYEVA; S BREIT; A WENZEL; R HANDGRETINGER; J BARAK; Moshe Oren; L AMLER; M SCHWAB (1995). NON-SYNTENIC AMPLIFICATION OF MDM2 AND MYCN IN HUMAN NEUROBLASTOMA.  Oncogene. 10:(6)1081-1086.  Abstract
74.
O EIZENBERG; A FABERELMAN; E GOTTLIEB; Moshe Oren; Varda Rotter; Michal Schwartz (1995). DIRECT INVOLVEMENT OF P53 IN PROGRAMMED CELL-DEATH OF OLIGODENDROCYTES.  EMBO Journal. 14:(6)1136-1144.  Abstract
73.
E SHAULIAN; I HAVIV; Yosef Shaul; Moshe Oren (1995). TRANSCRIPTIONAL REPRESSION BY THE C-TERMINAL DOMAIN OF P53.  Oncogene. 10:(4)671-680.  Abstract

1994

72.
Yoav Barak; E GOTTLIEB; T JUVENGERSHON; Moshe Oren (1994). REGULATION OF MDM2 EXPRESSION BY P53 - ALTERNATIVE PROMOTERS PRODUCE TRANSCRIPTS WITH NONIDENTICAL TRANSLATION POTENTIAL.  GENES & DEVELOPMENT. 8:(15)1739-1749.  Abstract
71.
Moshe Oren (1994). RELATIONSHIP OF P53 TO THE CONTROL OF APOPTOTIC CELL-DEATH.  Seminars in Cancer Biology. 5:(3)221-227.
70.
A CIECHANOVER; D SHKEDY; Moshe Oren; B BERCOVICH (1994). DEGRADATION OF THE TUMOR-SUPPRESSOR PROTEIN-P53 BY THE UBIQUITIN-MEDIATED PROTEOLYTIC SYSTEM REQUIRES A NOVEL SPECIES OF UBIQUITIN-CARRIER PROTEIN, E2.  Journal of Biological Chemistry. 269:(13)9582-9589.  Abstract
69.
E GOTTLIEB; R HAFFNER; T VONRUDEN; EF WAGNER; Moshe Oren (1994). DOWN-REGULATION OF WILD-TYPE P53 ACTIVITY INTERFERES WITH APOPTOSIS OF IL-3-DEPENDENT HEMATOPOIETIC-CELLS FOLLOWING IL-3 WITHDRAWAL.  EMBO Journal. 13:(6)1368-1374.  Abstract
68.
Ayelet Zauberman; A LUPO; T JUVEN; R HAFFNER; E GOTTLIEB; Yoav Barak; Moshe Oren (1994). TARGETS OF P53.  Journal of Cellular Biochemistry. 165-165.  Abstract
67.
Yoav Barak; A LUPO; Ayelet Zauberman; T JUVEN; R ALONIGRINSTEIN; E GOTTLIEB; Varda Rotter; Moshe Oren (1994). TARGETS FOR TRANSCRIPTIONAL ACTIVATION BY WILD-TYPE P53 - ENDOGENOUS RETROVIRAL LTR, IMMUNOGLOBULIN-LIKE PROMOTER, AND AN INTERNAL PROMOTER OF THE MDM2 GENE.  Cold Spring Harbor Symposia on Quantitative Biology. 59:225-235.  Abstract
66.
E GOTTLIEB; R HAFFNER; E YONISHROUACH; T VONRUDEN; E WAGNER; Moshe Oren (1994). WILD-TYPE P(53) ACTIVITY CONTRIBUTES TO DEPENDENCE ON HEMATOPOIETIC SURVIVAL FACTORS.  Apoptosis. 5:31-45.  Abstract

1993

65.
Noam Levy; E YONISHROUACH; Moshe Oren; Adi Kimchi (1993). COMPLEMENTATION BY WILD-TYPE P53 OF INTERLEUKIN-6 EFFECTS ON M1 CELLS - INDUCTION OF CELL-CYCLE EXIT AND COOPERATIVITY WITH C-MYC SUPPRESSION.  Molecular and Cellular Biology. 13:(12)7942-7952.  Abstract
64.
T JUVEN; Yoav Barak; Ayelet Zauberman; DL GEORGE; Moshe Oren (1993). WILD-TYPE P53 CAN MEDIATE SEQUENCE-SPECIFIC TRANSACTIVATION OF AN INTERNAL PROMOTER WITHIN THE MDM2 GENE.  Oncogene. 8:(12)3411-3416.  Abstract
63.
Alona Telerman; M TUYNDER; T DUPRESSOIR; B ROBAYE; F SIGAUX; E SHAULIAN; Moshe Oren; J ROMMELAERE; R AMSON (1993). A MODEL FOR TUMOR SUPPRESSION USING H-1 PARVOVIRUS.  Proceedings of the National Academy of Sciences of the United States of America. 90:(18)8702-8706.  Abstract
62.
Ayelet Zauberman; Yoav Barak; N RAGIMOV; Noam Levy; Moshe Oren (1993). SEQUENCE-SPECIFIC DNA-BINDING BY P53 - IDENTIFICATION OF TARGET SITES AND LACK OF BINDING TO P53MDM2 COMPLEXES.  EMBO Journal. 12:(7)2799-2808.  Abstract
61.
E SHAULIAN; Ayelet Zauberman; J MILNER; EA DAVIES; Moshe Oren (1993). TIGHT DNA-BINDING AND OLIGOMERIZATION ARE DISPENSABLE FOR THE ABILITY OF P53 TO TRANSACTIVATE TARGET GENES AND SUPPRESS TRANSFORMATION.  EMBO Journal. 12:(7)2789-2797.  Abstract
60.
Moshe Oren (1993). ALONI, YOSEF - (1936-1993) - OBITUARY.  Oncogene. 8:(6)1405-1405.
59.
N RAGIMOV; A KRAUSKOPF; N NAVOT; Varda Rotter; Moshe Oren; Y ALONI (1993). WILD-TYPE BUT NOT MUTANT-P53 CAN REPRESS TRANSCRIPTION INITIATION INVITRO BY INTERFERING WITH THE BINDING OF BASAL TRANSCRIPTION FACTORS TO THE TATA MOTIF.  Oncogene. 8:(5)1183-1193.  Abstract
58.
E YONISHROUACH; D GRUNWALD; Sylvia Wilder; Adi Kimchi; E MAY; JJ LAWRENCE; P MAY; Moshe Oren (1993). P53-MEDIATED CELL-DEATH - RELATIONSHIP TO CELL-CYCLE CONTROL.  Molecular and Cellular Biology. 13:(3)1415-1423.  Abstract
57.
Yoav Barak; T JUVEN; R HAFFNER; Moshe Oren (1993). MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY.  EMBO Journal. 12:(2)461-468.  Abstract

1992

56.
E SHAULIAN; Ayelet Zauberman; D GINSBERG; Moshe Oren (1992). IDENTIFICATION OF A MINIMAL TRANSFORMING DOMAIN OF P53 - NEGATIVE DOMINANCE THROUGH ABROGATION OF SEQUENCE-SPECIFIC DNA-BINDING.  Molecular and Cellular Biology. 12:(12)5581-5592.  Abstract
55.
F YEHIELY; Moshe Oren (1992). THE GENE FOR THE RAT HEAT-SHOCK COGNATE, HSC70, CAN SUPPRESS ONCOGENE-MEDIATED TRANSFORMATION.  Cell Growth & Differentiation. 3:(11)803-809.  Abstract
54.
Moshe Oren (1992). P53 - THE ULTIMATE TUMOR SUPPRESSOR GENE.  FASEB Journal. 6:(13)3169-3176.  Abstract
53.
Moshe Oren (1992). THE INVOLVEMENT OF ONCOGENES AND TUMOR SUPPRESSOR GENES IN THE CONTROL OF APOPTOSIS.  Cancer and Metastasis Reviews. 11:(2)141-148.
52.
Yoav Barak; Moshe Oren (1992). ENHANCED BINDING OF A 95-KDA PROTEIN TO P53 IN CELLS UNDERGOING P53-MEDIATED GROWTH ARREST.  EMBO Journal. 11:(6)2115-2121.  Abstract

1991

51.
O EIZENBERG; Moshe Oren (1991). REDUCED LEVELS OF ALPHA-1 (I) COLLAGEN MESSENGER-RNA IN CELLS IMMORTALIZED BY MUTANT P53 OR TRANSFORMED BY RAS.  Biochimica Et Biophysica Acta. 1129:(1)34-42.  Abstract
50.
D GINSBERG; F MECHTA; Moti Yaniv; Moshe Oren (1991). WILD-TYPE P53 CAN DOWN-MODULATE THE ACTIVITY OF VARIOUS PROMOTERS.  Proceedings of the National Academy of Sciences of the United States of America. 88:(22)9979-9983.  Abstract
49.
Ofra Halevy; J RODEL; Anat Peled; Moshe Oren (1991). FREQUENT P53 MUTATIONS IN CHEMICALLY-INDUCED MURINE FIBROSARCOMA.  Oncogene. 6:(9)1593-1600.  Abstract
48.
Dan Michael; F YEHIELY; E GOTTLIEB; Moshe Oren (1991). SIMIAN VIRUS-40 CAN OVERCOME THE ANTIPROLIFERATIVE EFFECT OF WILD-TYPE-P53 IN THE ABSENCE OF STABLE LARGE T-ANTIGEN-P53 BINDING.  Journal of Virology. 65:(8)4160-4168.  Abstract
47.
E YONISHROUACH; D RESNITZKY; Joseph Lotem; Leo Sachs; Adi Kimchi; Moshe Oren (1991). WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6.  Nature. 352:(6333)345-347.  Abstract
46.
D GINSBERG; S HIRAI; O PINHASIKIMHI; Moti Yaniv; Moshe Oren (1991). TRANSFECTED MOUSE C-JUN CAN INHIBIT TRANSFORMATION OF PRIMARY RAT EMBRYO FIBROBLASTS.  Oncogene. 6:(4)669-672.  Abstract
45.
D MICHALOVITZ; Ofra Halevy; Moshe Oren (1991). P53 MUTATIONS - GAINS OR LOSSES.  Journal of Cellular Biochemistry. 45:(1)22-29.  Abstract
44.
D GINSBERG; Dan Michael; Moshe Oren (1991). Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein.  Molecular and Cellular Biology. 11:(1)582-585.  Abstract

1990

43.
Ofra Halevy; D MICHALOVITZ; Moshe Oren (1990). Different tumor-derived p53 mutants exhibit distinct biological activities.  Science. 250:(4977)113-116.  Abstract
42.
D GINSBERG; Moshe Oren; Moti Yaniv; J PIETTE (1990). PROTEIN-BINDING ELEMENTS IN THE PROMOTER REGION OF THE MOUSE P53 GENE.  Oncogene. 5:(9)1285-1290.
41.
D MICHALOVITZ; Ofra Halevy; Moshe Oren (1990). Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.  Cell. 62:(4)671-680.
40.
D Eliyahu; Dan Yosef Michael; S. Eliyahu; O. Pinchas-Kimhi; Moshe Oren (1990). p53 — Oncogene or Anti-Oncogene?.  Oncogenes in Cancer Diagnosis. 125-134.

1989

39.
David Eliyahu; Dan MICHALOVITZ ; S ELIYAHU; O PINHASIKIMHI; Moshe Oren (1989). Wild-type p53 can inhibit oncogene-mediated focus formation.  Proceedings of the National Academy of Sciences of the United States of America. 86:(22)8763-8767.
38.
Ofra Halevy; A HALL; Moshe Oren (1989). STABILIZATION OF THE P53 TRANSFORMATION-RELATED PROTEIN IN MOUSE FIBRO-SARCOMA CELL-LINES - EFFECTS OF PROTEIN-SEQUENCE AND INTRACELLULAR ENVIRONMENT.  Molecular and Cellular Biology. 9:(8)3385-3392.
37.
D MICHALOVITZ; Abraham Amsterdam; Moshe Oren (1989). INTERACTIONS BETWEEN SV40 AND CELLULAR ONCOGENES IN THE TRANSFORMATION OF PRIMARY RAT-CELLS.  Current Topics in Microbiology and Immunology. 144:63-75.

1988

36.
S KRAISS; A QUAISER; Moshe Oren; M MONTENARH (1988). OLIGOMERIZATION OF ONCOPROTEIN-P53.  Journal of Virology. 62:(12)4737-4744.
35.
Abraham Amsterdam; Ayelet Zauberman; Gila Meir; O PINHASIKIMHI; BS SUH; Moshe Oren (1988). COTRANSFECTION OF GRANULOSA-CELLS WITH SIMIAN VIRUS-40 AND HA-RAS ONCOGENE GENERATES STABLE LINES CAPABLE OF INDUCED STEROIDOGENESIS.  Proceedings of the National Academy of Sciences of the United States of America. 85:(20)7582-7586.
34.
David Eliyahu; Naomi Goldfinger; O PINHASIKIMHI; G SHAULSKY; Y SKURNIK; N ARAI; Varda Rotter; Moshe Oren (1988). METH-A FIBRO-SARCOMA CELLS EXPRESS 2 TRANSFORMING MUTANT P53 SPECIES.  Oncogene. 3:(3)313-321.
33.
CA FINLAY; PW HINDS; TH TAN; David Eliyahu; Moshe Oren; AJ LEVINE (1988). ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE.  Molecular and Cellular Biology. 8:(2)531-539.
32.
Dan Michalovitz (Michael); O Pinhasi-Kimchi; D Eliyahu; Avri Ben-Ze'ev; M. Oren (1988). Complex Formation Between the p53 Cellular Tumor Antigen and Nuclear Heat Shock Proteins.  . 56:247-259.

1987

31.
D MICHALOVITZ; L FISCHERFANTUZZI; C VESCO; JM PIPAS; Moshe Oren (1987). Activated Ha-ras can cooperate with defective simian virus 40 in the transformation of nonestablished rat embryo fibroblasts.  Journal of Virology. 61:(8)2648-2654.  Abstract
30.
O SHOHAT; Moshik Greenberg; D REISMAN; Moshe Oren; Varda Rotter (1987). INHIBITION OF CELL-GROWTH MEDIATED BY PLASMIDS ENCODING P53 ANTISENSE.  Oncogene. 1:(3)277-283.

1986

29.
D MICHALOVITZ; David Eliyahu; Moshe Oren (1986). Overproduction of protein p53 contributes to simian virus 40-mediated transformation.  Molecular and Cellular Biology. 6:(10)3531-3536.  Abstract
28.
O PINHASIKIMHI; D MICHALOVITZ; Avri Ben-Ze'ev; Moshe Oren (1986). SPECIFIC INTERACTION BETWEEN THE P53 CELLULAR TUMOR-ANTIGEN AND MAJOR HEAT-SHOCK PROTEINS.  Nature. 320:(6058)182-185.
27.
L KACZMAREK; Moshe Oren; R BASERGA (1986). COOPERATION BETWEEN THE P53 PROTEIN TUMOR-ANTIGEN AND PLATELET-POOR PLASMA IN THE INDUCTION OF CELLULAR DNA-SYNTHESIS.  Experimental Cell Research. 162:(1)268-272.
26.
B MOAV; M HOROWITZ; JB COHEN; G RECHAVI; Erez Eliyahu; Moshe Oren; David Givol (1986). STRUCTURE AND ACTIVITY OF THE TRANSLOCATED C-MYC IN MOUSE PLASMACYTOMA XRPC-24.  Gene. 48:(3-Feb)297-300.

1985

25.
David Eliyahu; Dan Michalovitz ; Moshe Oren (1985). Overproduction of p53 antigen makes established cells highly tumorigenic.  Nature. 316:(6024)158-160.  Abstract
24.
R ZAKUTHOURI; B BIENZTADMOR; David Givol; Moshe Oren (1985). HUMAN P53 CELLULAR TUMOR-ANTIGEN - CDNA SEQUENCE AND EXPRESSION IN COS CELLS.  EMBO Journal. 4:(5)1251-1255.
23.
B BIENZTADMOR; R ZAKUTHOURI; S LIBRESCO; David Givol; Moshe Oren (1985). THE 5' REGION OF THE P53 GENE - EVOLUTIONARY CONSERVATION AND EVIDENCE FOR A NEGATIVE REGULATORY ELEMENT.  EMBO Journal. 4:(12)3209-3213.
22.
A ROGEL; Malka Popliker; CG WEBB; Moshe Oren (1985). P53 CELLULAR TUMOR-ANTIGEN - ANALYSIS OF MESSENGER-RNA LEVELS IN NORMAL ADULT TISSUES, EMBRYOS, AND TUMORS.  Molecular and Cellular Biology. 5:(10)2851-2855.
21.
OW MCBRIDE; DE MERRY; Moshe Oren; David Givol (1985). HUMAN P53 CELLULAR TUMOR-ANTIGEN IS ON CHROMOSOME 17P13.  Cytogenetic and Genome Research. 40:(4-Jan)694-695.  Abstract
20.
Moshe Oren (1985). THE P53 CELLULAR TUMOR-ANTIGEN - GENE STRUCTURE, EXPRESSION AND PROTEIN-PROPERTIES.  Biochimica Et Biophysica Acta. 823:(1)67-78.
19.
MM LEBEAU; CA WESTBROOK; MO DIAZ; JD ROWLEY; Moshe Oren (1985). TRANSLOCATION OF THE P53 GENE IN TRANS-(15-17) IN ACUTE PROMYELOCYTIC LEUKEMIA.  Nature. 316:(6031)826-828.

1984

18.
David Eliyahu; Adva Raz; P GRUSS; David Givol; Moshe Oren (1984). PARTICIPATION OF P53 CELLULAR TUMOR-ANTIGEN IN TRANSFORMATION OF NORMAL EMBRYONIC-CELLS.  Nature. 312:(5995)646-649.
17.
B BIENZ; R ZAKUTHOURI; David Givol; Moshe Oren (1984). ANALYSIS OF THE GENE CODING FOR THE MURINE CELLULAR TUMOR-ANTIGEN P53.  EMBO Journal. 3:(9)2179-2183.
16.
HH CZOSNEK; B BIENZ; David Givol; R ZAKUTHOURI; DD PRAVTCHEVA; FH RUDDLE; Moshe Oren (1984). THE GENE AND THE PSEUDOGENE FOR MOUSE P53 CELLULAR TUMOR-ANTIGEN ARE LOCATED ON DIFFERENT CHROMOSOMES.  Molecular and Cellular Biology. 4:(8)1638-1640.
15.
NT HAYNER; M GOYETTE; Moshe Oren; N FAUSTO (1984). MODULATION OF P53 EXPRESSION DURING LIVER-REGENERATION.  Journal of Cell Biology. 99:(4)A450-A450.  Abstract
14.
O PINHASI; Moshe Oren (1984). EXPRESSION OF THE MOUSE P53 CELLULAR TUMOR-ANTIGEN IN MONKEY CELLS.  Molecular and Cellular Biology. 4:(10)2180-2186.
13.
D WOLF; S ADMON; Moshe Oren; Varda Rotter (1984). ABELSON MURINE LEUKEMIA VIRUS-TRANSFORMED CELLS THAT LACK P53 PROTEIN-SYNTHESIS EXPRESS ABERRANT P53 MESSENGER-RNA SPECIES.  Molecular and Cellular Biology. 4:(3)552-558.

1983

12.
Moshe Oren; B BIENZ; David Givol; G RECHAVI; R ZAKUT (1983). ANALYSIS OF RECOMBINANT DNA CLONES SPECIFIC FOR THE MURINE-P53 CELLULAR TUMOR-ANTIGEN.  EMBO Journal. 2:(10)1633-1639.
11.
Moshe Oren; AJ LEVINE (1983). MOLECULAR-CLONING OF A CDNA SPECIFIC FOR THE MURINE P53 CELLULAR TUMOR-ANTIGEN.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 80:(1)56-59.
10.
R ZAKUTHOURI; Moshe Oren; B BIENZ; V LAVIE; S HAZUM; David Givol (1983). A SINGLE GENE AND A PSEUDOGENE FOR THE CELLULAR TUMOR ANTIGEN-P53.  Nature. 306:(5943)594-597.
9.
NC REICH; Moshe Oren; AJ LEVINE (1983). 2 DISTINCT MECHANISMS REGULATE THE LEVELS OF A CELLULAR TUMOR-ANTIGEN, P53.  Molecular and Cellular Biology. 3:(12)2143-2150.

1982

8.
D GIDONI; A SCHELLER; B BARNET; P HANTZOPOULOS; Moshe Oren; C PRIVES (1982). DIFFERENT FORMS OF SIMIAN VIRUS-40 LARGE TUMOR-ANTIGEN VARYING IN THEIR AFFINITIES FOR DNA.  Journal of Virology. 42:(2)456-466.

1980

7.
Moshe Oren; Ernest Winocour; C PRIVES (1980). DIFFERENTIAL AFFINITIES OF SIMIAN VIRUS-40 LARGE TUMOR-ANTIGEN FOR DNA.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 77:(1)220-224.

1979

6.
C PRIVES; Y BECK; D GIDONI; Moshe Oren; H SHURE (1979). DNA-BINDING AND SEDIMENTATION PROPERTIES OF SV40 T-ANTIGENS SYNTHESIZED INVIVO AND INVITRO.  Cold Spring Harbor Symposia on Quantitative Biology. 44:123-130.
5.
C PRIVES; H SHURE; D GIDONI; Y BECK; Moshe Oren (1979). COMPARISON OF SIMIAN-VIRUS-40 BIG AND LITTLE T-ANTIGENS.  Israel Medical Association Journal. 15:(1)100-101.  Abstract

1978

4.
Moshe Oren; Sara Lavi; Ernest Winocour (1978). STRUCTURE OF A CLONED SUBSTITUTED SV40-GENOME.  Virology. 85:(2)404-421.

1977

3.
Y GLUZMAN; J DAVISON; Moshe Oren; Ernest Winocour (1977). PROPERTIES OF PERMISSIVE MONKEY CELLS TRANSFORMED BY UV-IRRADIATED SIMIAN VIRUS-40.  Journal of Virology. 22:(2)256-266.

1976

2.
Moshe Oren; EL KUFF; Ernest Winocour (1976). PRESENCE OF COMMON HOST SEQUENCES IN DIFFERENT POPULATIONS OF SUBSTITUTED SV40-DNA.  Virology. 73:(2)419-430.
1.
Moshe Oren; EL KUFF; Ernest Winocour (1976). COMMON HOST SEQUENCES IN SUBSTITUTED SIMIAN VIRUS-40 DNA.  Israel Medical Association Journal. 12:(11)1390-1390.  Abstract